Molecular classification and fertility-sparing outcomes in endometrial cancer and atypical endometrial hyperplasia
Biomolecules and Biomedicine · 2025
DOI: 10.17305/bb.2025.12445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2025. Verfasst von Jiayi Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Medical Key Laboratory for Preventi…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Fertility Preservation, Endometrial Hyperplasia. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Molecular classification has emerged as a critical tool for guiding personalized treatment in endometrial cancer (EC) and atypical endometrial hyperplasia (AEH). This retrospective study aimed to assess the impact of molecular classification on fertility-sparing treatment outcomes in patients diagnosed with EC and AEH who underwent fertility preservation therapy between 2006 and 2021. Patients were categorized into four molecular subtypes using immunohistochemistry (IHC) and Sanger sequencing, based on the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE): POLE-ultramutated, mismatch repair (MMR) deficient (MMRd), p53 abnormal (p53abn), and p53 wild-type (p53wt). All patients were evaluated for oncological prognosis and fertility outcomes, with a total of 103 patients included in the analysis. Recurrence rates exhibited significant differences among the molecular classifications, with the lowest recurrence rate observed in the p53wt subtype (19.7%), followed by MMRd (30.4%), POLE-ultramutated (66.7%), and p53abn (71.4%) subtypes. Multivariate Cox regression analysis indicated that the p53abn subtype was a significant risk factor for recurrence following conservation therapy when compared to the p53wt subtype. Additionally, there was a notable disparity in standard surgical treatment due to treatment failure, with operation rates of 7.5%, 19.2%, 66.7%, and 57.1% for the p53wt, MMRd, POLE-ultramutated, and p53abn subtypes, respectively. Regarding fertility outcomes, the p53wt group demonstrated the highest pregnancy rate after achieving a complete response compared to the other subtypes; however, no significant differences were observed in overall pregnancy outcomes. The ProMisE molecular classification holds significant prognostic value for patients with EC and AEH undergoing fertility-sparing treatment. Among the molecular subtypes, p53wt appears to be the most favorable for fertility-preserving interventions. This study provides essential insights into reproductive outcomes for this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Medical Key Laboratory for Prevention and Treatment of Malignant Gynecological Tumor, China.
- Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zitieren
APA
Wang, J., Jiang, G., Yan, S., Tian, Y., Jin, Y., Fu, H., Si, L., Cai, M., Liu, X., & Guo, R. (2025). Molecular classification and fertility-sparing outcomes in endometrial cancer and atypical endometrial hyperplasia. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2025.12445
Vancouver
Wang J, Jiang G, Yan S, Tian Y, Jin Y, Fu H, et al. Molecular classification and fertility-sparing outcomes in endometrial cancer and atypical endometrial hyperplasia. Biomolecules and Biomedicine. 2025. doi:10.17305/bb.2025.12445
BibTeX
@article{Wang2025,
author = {Wang, Jiayi and Jiang, Guozhong and Yan, Shuping and Tian, Yanpeng and Jin, Yuxi and Fu, Hanlin and Si, Lulu and Cai, Mingbo and Liu, Xueyan and Guo, Ruixia},
title = {Molecular classification and fertility-sparing outcomes in endometrial cancer and atypical endometrial hyperplasia},
journal = {Biomolecules and Biomedicine},
year = {2025},
doi = {10.17305/bb.2025.12445}
}
EUVIMED